Cancer Immunology - Subramanian, Subree||Zhao, Xianda
English[eng]
Keywords: NKG2D||CAR T||IL-7||prostate cancer||cell therapy||CD19-CAR-T||B cell aplasia||KIR||PD-1||inhibitory CAR||tumor-infiltrating lymphocytes||tumor microenvironment||immunotherapy||NK cells||cancer stem cells (CSCs)||antibody-dependent cellular cytotoxicity (ADCC)||differentiation||cytotoxicity||IFN-Î||osteoclasts||MICA/B mAb||DNA methylation||RNA methylation||S-adenosylmethionine (SAM)||cancer||innate immunity||adaptive immunity||T cells||m6A||PD-L1||resistance||immune checkpoints||cancer vaccine||combination immunotherapy||TCR diversity||organ transplantation||carcinoma||epidemiologic studies||immunosuppression||CTLA-4||Treg cells||immune checkpoint inhibitors||CD28||antigen-presenting cells||IL15||colon cancer||melanoma||uveal||BAP1||anti-PD-1||anti-CTLA-4||TIL||classical and endemic Kaposi Sarcoma||systemic treatment||multi-state modelling||treatment free interval||chemotherapy||interferon||triple negative breast cancer||immunomodulation||bispecific antibody||sortase A||chemo-enzymatic approach||anti-CD20 antibody||Fab||BiFab||colorectal cancer||dendritic cells||Atypical Chemokine Receptor 4 (ACKR4)||T-cell priming||immune checkpoint blockade||primary liver cancer||kynurenine pathway||immune evasion||indoleamine 2,3 dioxygenase 1||tryptophan 2,3 dioxygenase 2||IDO inhibitor||antigen presenting cells||n/a